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Abstract
Kidney clip-induced hypertensive rats were treated with two classes of anti-hypertensive drugs:
beta-blockers and calcium channel blockers. Their blood pressures were monitored for several
months, as were those of normotensive control rats. The hypertensive rats responded to treatment
with drops in blood pressure, in some cases of greater than 70 mmHg. The variability of blood
pressure was found to be similar in all three groups of rats.
Horseradish peroxidase spot size experiments were performed on rats that had been treated with
cytotoxic agents to induce apoptosis. Spot frequency was observed to be lower in these treated
animals than in control subjects. We propose explanations for this unexpected result.
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Chapter 1: The effect of beta blocking and calcium channel blocking anti-hypertensive
drugs on kidney clip-induced hypertensive rats

1.1: Introduction
Another student in the lab, Dr. Jimmy Toussaint, had investigated the role of aquaporin-1
(AQP1) in the progress of atherosclerosis, a topic addressed in great detail in (26). One aspect of
that work was the effect of hypertension on the expression of AQP1 in rat endothelial cells; it
increased such expression. As one of several controls, he sought to induce hypertension in eight
rats, reverse the hypertension with drugs, and then measure aquaporin-1 expression. To this end,
he performed the two clip, one kidney Goldblatt procedure on eight male Sprague Dawley rats.
The purpose of this control experiment was to rule out the possibility that some aspect of this
surgery aside from the elevated blood pressure it induces had an independent effect on AQP1
expression. All animal work was approved by the Institutional Animal Care and Use Committee
(IACUC) of City College. In this procedure, described in Frei (6) and Mohring (15) the
abdominal cavity of the rat is opened and a silver clip with a gap width of 200 microns is placed
on the renal artery. This restricts blood flow to the kidney and induces various hormonal changes
that eventually result in hypertension. Six of the animals developed hypertension, and it was my
goal to medicate them to lower their blood pressure.
Toussaint had already performed a version of this experiment in which the drug of choice was
captopril, an angiotensin converting enzyme (ACE) inhibitor. In that study, hypertensive rats that
had been restored to normotensive with captopril were found to have far lower levels of AQP1
than both healthy, normotensive, untreated rats and sham-operated rats (in the sham operation,
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every step of the Goldblatt procedure is performed except for placement of the arterial clip).
Toussaint therefore concluded that the Captopril had an independent effect on AQP1. He later
conducted a literature review and found published evidence (31) of another ACE inhibitor’s
negative effect on AQP1 expression (26).
1.2: Materials and Methods
In light of these considerations, drugs of different classes were selected for this batch of six
hypertensive rats. The batch was subdivided into two groups, each including one rat with blood
pressure above 200 mmHg and two with blood pressure of approximately 160 mmHg. One
group was treated with generic atenolol (Teva), a beta blocker, and the other with diltiazem
(Teva or Mylan), a calcium channel blocker.
The goal, then, was to lower these rats’ blood pressures. Three were given generic atenolol, a
beta blocker in a dose range of 10 to 140 mg/kg/day. The other three were given generic
diltiazem, a calcium channel blocker in a dose range of 40 to 200 mg/kg/day. The doses were
increased gradually, and all rats were monitored closely by researchers and animal facility staff
for signs of acute illness or distress. The drugs were purchased from local retail pharmacies in
pill form and crushed and ground into powder in a mortar and pestle. Initially, both drugs were
added to the rats’ drinking water. To achieve the intended dose, the rats’ daily water intake was
measured over several days and the concentrations adjusted accordingly. Unfortunately, as noted
in (6), rats have been known to avoid aqueous diltiazem solution, even at the risk of dehydration.
Indeed, such was the case in our study, leading to two problems: the rats became dehydrated, and
they did not receive the intended dose of diltiazem. Additionally, at high enough doses, even the
atenolol solution was avoided, leading to some dehydration in that group as well. At various
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points in the study, dehydrated rats were given Pedialyte (Abbot Labs), a sweetened cherry
flavored beverage fortified with electrolytes, as a short-term antidote to dehydration.
To combat the less acute but more fundamental problem of how to have the rats ingest the drug,
we decided to mix the diltiazem into a treat for the rats. On the advice of the institutional
veterinarian, we initially selected peanut butter (Associated brand, purchased at a local
supermarket) as this treat. However, this proved ineffective, i.e. the rats ate either some or none
of the peanut butter and could not be assumed to be receiving the intended dose. Next we tried
replacing the peanut butter with Bio-serv bacon flavored Transgenic Dough Diet, a calorie dense
diet supplement or replacement with the texture of cookie dough that is designed to stimulate
appetite. This proved much more popular with the rats, meaning they almost always finished the
entire portion, and had the added benefit of countering weight loss. See (15) for other evidence
of lower body weight in hypertensive rats. Eventually, all rats in the calcium channel blocker
group and one in the beta blocker group received this Transgenic Dough Diet.
Another problem encountered was partial response. That is, blood pressure decreased in all
animals treated with the initial dose but did not reach normotensive levels. The first step taken to
address this problem was to simply increase the dose, and for the beta blocker group rats this
eventually proved sufficient. However, in the calcium channel blocker group, blood pressure
remained above normotensive levels even at higher doses, and so a second drug in the same
class, amlodipine (Camber Pharmaceuticals), was added to those rats’ diets in a dose ranging
from 1 to 10 mg/kg/day. Again, the dose was increased gradually, and all animals were closely
monitored for signs of acute illness or distress.
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Systolic blood pressure was measured by a non-invasive inflatable tail cuff method
(ADInstruments). We did not monitor diastolic blood pressure, because these readings are less
accurate and less reproducible by tail cuff measurements.
1.3: Results and Discussion
The graphs below represent systolic blood pressure recordings taken before the procedures and
approximately once a week between the surgery and Toussaint’s AQP1 experiment, which
involved euthanizing the rats. The measurements were taken by Toussaint and Chirag Raval. In
all the graphs, the first measurement was taken before the surgery. The surgeries were performed
between September 4 and September 11. The six hypertensive rats were first given medication in
late October and their doses were gradually increased over subsequent weeks and months. The
values reported are averages of 4 to 15 measurements taken in one sitting, with error bars
representing positive and negative spread about the mean. For the control rats (figs. 1.7-8), after
6 consecutive sets of post-surgical measurements all showed normal blood pressure, no more
measurements were recorded until just prior to euthanasia in the next stage of the experiment.
There is also a month-long gap between the last two measurements in figure 1.6. This represents
a time when that particular rat showed various signs of illness, including low body weight and
frequent dehydration, and its pulse and blood pressure could not be detected by our measuring
equipment.
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Figure 1.1: Blood pressure time course of rat A
Surgery: 9/11
Initiation of drug treatment: 10/19
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Figure 1.2: Blood pressure time course of rat B
Surgery: 9/11
Initiation of drug treatment: 10/19
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Figure 1.3: Blood pressure time course of Rat C
Surgery: 9/12
Initiation of drug treatment: 10/19
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Figure 1.4: Blood pressure time course of Rat D
Surgery: 9/12
Initiation of drug treatment: 10/19
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Figure 1.5: Blood pressure time course of Rat E
Surgery: 9/10
Initiation of drug treatment: 10/19
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Figure 1.6: Blood pressure time course of Rat H
Surgery: 9/12
Initiation of drug treatment: 10/19
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Figure 1.7: Blood pressure time course of Rat F
Surgery: 9/4
No drug treatment
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Figure 1.8: Blood pressure time course of Rat G
Surgery: 9/10
No drug treatment
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First note the different baseline blood pressure levels recorded about one month after surgery,
before initiation of drug treatment. The two controls in this study underwent the full Goldblatt
procedure, including placement of the clip, but failed to develop hypertension. Additionally,
among the hypertensive animals, two were severely hypertensive (systolic blood pressure (SBP)
> 200 mmHg) and four only moderately (SBP ~ 160 mmHg). Slight errors (on the order of tens
of microns) in the gap spacing of the clips, as well as small variations in renal artery diameter
among the animals, can go a long way toward explaining this variation, which has been found by
other investigators (6, 9). Frei, for example, reports that only 60% of his kidney-clipped rats
developed hypertension, and among the hypertensives there was a 12 to 14 point spread about
the mean systolic blood pressure (6). It is reasonable to conjecture that, as the blood pressure
increase is induced by constriction of the renal artery, variations in the gap width of the clip and
the diameter of the vessel, which lead to variations in the level of constriction, would in turn
cause variations in the level of hypertension. Also consider rat weight at the time of surgery, at
least the most intuitively obvious indicator of vessel diameter. The graph below plots ultimate
blood pressure as a function of rat weight at surgery. While there is a good deal of scatter and the
total number of subjects is a rather low eight, the graph is at least suggestive of a correlation.
Unfortunately, information on the deviation of the actual gap width of the clips from the
attempted 200 microns is unavailable. It could be instructive to plot that data against ultimate

19

levels of hypertension and see whether it is a clearer predictor than rat weight.

Figure 1.9: blood pressure versus rat weight at surgery

Next, note the initial drop in blood pressure shortly after initiation of drug treatment at the end of
October in all six cases. These drops, in all cases except case C, were not all the way down to
normotensive levels. Also, in the diltiazem group, these decreases were followed shortly by
relapses, as more diltiazem was added to the rats’ drinking water (in attempt to lower blood
pressure still further, to normotensive levels) and they stopped drinking.
Some results seem almost obvious upon a close reading of the literature, others are less readily
apparent but help to explain how previous experiments have been designed, and a few are truly
novel. First, all rats responded to drug treatment at typical doses with decreases in blood pressure
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in good agreement with previously reported results. Next, rats do tend to avoid diltiazem, as well
as atenolol at high enough doses, even at the risk of dehydration. It should be pointed out,
however, that this study was not the first to attempt to administer diltiazem via drinking water.
This study, as mentioned above, used pill forms of the drugs purchased from a local pharmacy,
mainly for reasons of financial expense. These pills contain, by weight, far more inactive
material than active (by a factor of approximately 2 to 40, depending on the drug). First there is
the remote chance that so-called inactive ingredients actually have some effect that may
introduce artifact. More troubling, however, is the tendency of the starches and other components
to precipitate out of solution. One hopes that the precipitate contains only fillers, coloring and
such and that all of the medically active substance remains dissolved in solution, but this is
difficult to verify and, indeed, was not verified for this study. Another decision made for reasons
of cost was to deliver the drugs via drinking water, as injecting the solution directly into the
animals’ mouths would have required either recruiting trained animal handlers or investing in
training the researchers involved in the study. In addition to the dehydration problem mentioned
above, the rats grew over the course of the study and began to drink more than earlier
measurements indicated. Further, variations in severity of the rats’ renal hypertension, a disease
known to cause thirst (15), also led to changes in water intake. These factors help explain why
other groups went to all the trouble and expense of obtaining pure forms of the drug from
chemical suppliers and administering them to their animals by the more standardized method of
daily oral injection. These concerns must certainly be taken into account in planning future work.
One finding bears mentioning, because it was not observed in a review of the literature on
treatment of hypertension in rats with these drugs. This study found that, at high enough doses
(which obviously did not prove lethal, or even immediately harmful), drops in blood pressure of
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more than 70 points were possible with both atenolol and the diltiazem/amlodipine combination.
One rat was even restored all the way from severely hypertensive to normotensive, although that
piece of data should be treated with great care, as that rat exhibited other signs of illness for most
of the last two months of the study, and its blood pressure proved unusually difficult to measure.
1.4: A note on blood pressure variability
After completing the above blood pressure study, our group learned, in private communication
with pharmaceutical industry researchers, of interest in not only the level of blood pressure but
also the level of variation of blood pressure in drug treated hypertensive subjects. This is in
addition to the well-known problem of error in indirect blood pressure measurement. Since they
have already studied spontaneously hypertensive rats, they are especially interested in kidneyclipped hypertensive rats, as these are not genetic mutants and are, therefore, considered more
representative of the general rat population. Millar-Craig (14), referring to human patients, noted
this issue in 1978, and our experience in this study confirmed that the problem has not gone
away since. Beyond this, there is a tendency of blood pressure to vary as function of different
factors, such as season (2) and time of day (12). In this study, since measuring variability was not
the original goal, no precautions were taken to ensure that measurements were consistently taken
at the same time of day. Depending on the researchers’ schedules and how long it took for the
rats to become sufficiently calm and sedentary to allow for measurement, the recordings were
taken in the morning, afternoon, or evening.
Obviously, some understanding of how blood pressure fluctuates is necessary for effective
monitoring and treatment of hypertension. In addition to that, however, increased variation in
blood pressure is a known indicator of hypovolemia (22), and decreased variation may be

22

important as a predictor of kidney disease (5), indicating that this measure may be an important
independent health factor. Clearly, then, if the goal of drug therapy of hypertension is to return
patients to the level of health and functioning of normotensive patients, then comparing blood
pressure variation in untreated normotensives and treated hypertensives is a reasonable next step
after bringing the mean pressures of the two groups within the same range.
To this end, we retrospectively examined the variability of blood pressure levels in our three
groups of rats: beta blocker treated (n=3), calcium channel blocker treated (n=3) and
normotensive control (n=2). Following Balansard (1) and others, we calculated coefficients of
variability (CV) for the eight series of measurements. This measure is simply the standard
deviation divided by the mean. Included were all data for the normotensive rats and data
collected after approximately two weeks of drug treatment for the hypertensives. The results are
tabulated below.
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Table 1.1 Coefficients of variation for treated and untreated rats
Beta Blocker

Calcium Channel
Blocker

Normotensive
Control

Rat A, Figure 1.1

Rat D, Figure 1.4

Rat F, Figure 1.7

0.0558

0.136

0.133

Rat B, Figure 1.2

Rat E, Figure 1.5

Rat G, Figure 1.8

0.163

0.0851

0.0573

Rat C, Figure 1.3

Rat H, Figure 1.6

0.0580

0.190

A cursory look at the above table brings a single word to mind: noise. The two normotensives
have widely divergent CV’s, and four of six of the hypertensive CV’s fall within or just outside
(0.133 versus 0.136) that range. One reassuring entry is the 0.190 for one of the calcium channel
blocker treated rats. This rat’s high variability corresponds to the observations and experience of
all researchers involved in the project. It exhibited dehydration, low body weight, and other signs
of ill health for much of the study; its blood pressure proved far more difficult to measure than
those of the other rats; and a plot of its blood pressure measurements over time (figure 1.6, rat H)
looks almost sinusoidal.
Also reassuring is a look at the literature on human blood pressure measurement. Peixoto (21)
took indirect blood pressure measurements of hemodialysis patients and included those currently
taking antihypertensive drugs as long as their drug regimens remained unchanged for the
duration of the study. He found CV’s based on their systolic blood pressure ranging from 0.075
all the way to 0.167, depending on the measuring procedure. Mancia (13) excluded all patients
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with major diseases aside from hypertension, excluded those who had been treated with
antihypertensive drugs, measured blood pressure by a direct invasive technique, and used a study
population of 89 people. These precautions yielded long term systolic blood pressure variability,
as measured by CV, of 0.08 to 0.10. (As a point of interest, the lower variability was seen in the
severely hypertensive group.) Musso (16) notes that office sphygmomanometry is subject to
“error as high as 38 mmHg.” And remember that rats, even in a warm, dark and quiet
environment, cannot be expected to hold still, although we did attempt to encourage this by
providing the rats with a quiet, warm, and dark environment for approximately an hour before
and during the measurement routine.
In light of these considerations, the values in the table above , while they unfortunately fail to say
anything definitive about the differences in blood pressure variability in normotensive and
treated hypertensive rats due to the small sample size, do suggest that the methods selected for
monitoring the rats’ blood pressures yielded results well within reported ranges.
One methodological point does bear mentioning. The coefficient of variability is essentially a
normalized standard deviation. As such, it indicates of how far observations vary from the
overall mean. It seems a perfectly appropriate (if somewhat blunt) measure for the medical
studies cited above: the blood pressure is not expected to change, and this value quantifies the
deviation from that expectation. Similarly, one can imagine a study similar to ours in which rats
are given a constant dose of an antihypertensive drug, except, perhaps, for adjustments to
account for weight changes. There too, we would expect a constant mean with some variation,
and we could measure this variation. However, in our case, the rats’ doses were regularly
increased until they became normotensive, or as close as we considered possible, at which point
they were euthanized in the next stage of the experiment, rather than being maintained at that
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dose and monitored for an extended period of time. There were also points at which the rats’
doses effectively decreased, for various reasons described above, e.g. they stopped eating or
drinking the drug-containing substance. If one were to partition the data into different regions
based on dose, regions in which one would expect a constant mean, one would in most cases find
only one or two sets of measurements between dose changes, for the following reasons. 1)
Measurements were taken once or twice a week, while dose changes often took a number of days
to implement due to rat taste preferences. 2) The experimental protocol called for rat euthanasia
to be carried out approximately one week after a stable lower blood pressure had been attained,
before the rats reached a critical age and weight. This did not allow us the time necessary to
monitor the rats’ blood pressures during extended drug treatment at a constant dose.
In light of this, if the treated rats had shown greater variability than the normotensives, it would
be unwarranted to ascribe this increase to the drugs. However, the treated rats, with the exception
of one with other health problems, showed variability quite similar to that of the normotensives
(slightly smaller for the beta blocker group and slightly larger for the healthy rats in the calcium
channel blocker group). This suggests two ideas. First, CV may be a fairly crude measure of
variability. Second, and more interestingly, the variability introduced by an antihypertensive
drug regimen in a small sample set seems to be only slightly greater than that of the ordinary
dynamic nature of physiology. One also needs to assess the effect of measurement error, but
recall Mancia’s CV’s of 0.08 to 0.1 even when measuring blood pressure directly.
The portion of the experiment that seeks to quantify AQP-1 expression in these rats’ aortic
endothelial cells is currently underway, under Toussaint’s direction.
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1.5: Conclusion
If we were to set out to quantify blood pressure variability, we would design the study
differently. We would use the same method of hypertension induction and probably the same
drugs to treat it. However, we would be careful to consistently measure blood pressure at the
same time of day. Even more importantly, we would decide on a dose, tune it according to rat
response, and then maintain the rats at that dose for a number of weeks or months, during which
time we would continually monitor blood pressure.
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Chapter 2: HRP spot frequency in rat aorta after chemically induced apoptosis
Introduction
For decades now, researchers such as Chuang (4), Stemerman (25), and Shou (24) have used
tracer studies to characterize mass transfer into artery, and especially aorta, walls. They have
found focal leakage. That is, intense spots of accumulated tracer tend to form rather than (or in
addition to, in the case of small tracers) a uniform darkening. Some have used tagged lowdensity lipoprotein (LDL); others have used Evans Blue albumin or horseradish peroxidase. The
peroxidase molecule, while significantly smaller than the 22 nanometer diameter LDL, is, at a
diameter of 6 nanometers, far larger than water and is believed to pass through the endothelial
layer and into the artery wall far more easily through so-called leaky junctions, or unusually wide
gaps between cells, as proposed by Weinbaum (29). For a more extensive review of the literature
on spot size studies of mass transfer into artery walls, see Yu (32).
Materials and Methods
All procedures were IACUC approved. The control experiment followed the method of Yu, with
chemicals and other materials sourced from the same suppliers, with one modification. As Yu
reports (32),
“To prepare the tracer, we dissolve 0.58g NaCl in 100 ml distilled water; then add 0.024 g HRP (for a 300
g rat) in 1mL normal saline. All procedures are IACUC approved.
30 mg Pentobarbital Sodium/kg body weight rat in a 1% solution (100 mg Pentobarbital Sodium in 10 ml
of distilled water, shaken gently) by intraperitoneal injection anesthetizes the rat. We shave the rat’s left leg, dissect
it and cannulate the left femoral vein and artery… We intubate the rat by attaching its trachea to a rodent
respirator…
We inject 1ml HRP and 0.5 - 1ml Heparin (5000 units/1 ml, Elkins-Sinn Inc. NJ). At 0.5, 1, 2… min blood
circulation, an overdose of Pentobarbital Sodium sacrifices the rat. After flushing with 10ml PBS (Phosphate
Buffered Saline; Sigma) and then perfusion-fixing the vessels in situ at room temperature with 1% Glutaraldehyde
(Sigma) (1 ml 50% Glutaraldehyde in 50 ml PBS) introduced into the carotid vein and artery and draining from the
femoral arteries, we excise the thoracic aorta… We prepare the excised vessels for examination by peeling away the
connective tissues and the adventitia, further fix them in 1% Glutaraldehyde for 1 hour [or overnight], rinse with
PBS three time to wash out the fixative and run the HRP-DAB reaction to develop the tracer spot. We dissolve
0.045 g DAB in a solution of 5 ml 0.3M Tris (0.182 g Tris (MW=121.1) in 5 ml H 2O) in 25 g distilled water, add 20
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μl of 30% H2O2, followed by 1M HCl to adjust the pH to 7.0~7.4 and then place the tissue in it. The DAB solution is
changed after 30 min and allowed to continue for another 30 min. The tissue is washed with PBS solution and
prepared on slides for en face examination with an Olympus BX51 light microscope. The reaction product is brown,
and so the leak is a brown spot. Since HRP can slowly penetrate normal junctions, focal spots coexist with diffuse
staining as in (14). We count the number of HRP spots by eye and measure the area of each piece of tissue. We then
calculate the leakage frequency” [in spots per square millimeter].

The modification in the experiments reported here is that the rats were given a larger
initial dose of pentobarbital anesthetic of 60 mg/kg. In the apoptosis experiment, the rats were
given 5 micrograms (ug) per kilogram of body weight of tumor necrosis factor alpha (TNFA)
and 0.75 mg/kg of cycloheximide, both purchased from Sigma Aldrich, intravenously through
the femoral vein. The rats were also given periodic booster doses of pentobarbital, based on
response to paw-pinch tests and breathing rate, to keep them unconscious over the course of this
longer experiment. In one experiment reported here, the drugs were injected in 4 equally divided
boluses over half an hour. Since that method appeared to cause respiratory distress, it was
rejected in the next 2 experiments in favor of continuous infusion, also over half an hour, which
seemed to cause less distress. On the advice of another researcher, Dr. Limary Cancel, who had
performed similar experiments on aortic endothelial cell monolayers, we allowed the drugs to
circulate for 4 hours to take effect. We then performed the standard HRP experiment (see above).
The images below are photographs taken with an Olympus consumer-grade digital camera
mounted on an Olympus BX51 optical microscope. The magnification of the microscope was
100x and that of the camera's zoom lens 3x. The images were further enlarged in the process of
publishing them in this document.

Results and Discussion
We were concerned about the short biological half life of TNFA. Zahn (33) reports it as 5-8
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minutes at a dose of 2 ug/kg administered to rats over half an hour and 30 minutes at 10 or more
ug/kg. However, we decided to proceed, on the thinking that, though the drug may be eliminated
fairly quickly, the damage it does may not be completely repaired in 4 hours.
The images below show control HRP spots at circulation at circulation times of 30, 60, and 120
seconds. The 4 minute experiment was not attempted, because other researchers (4, 32) have
reported nearly uniform leakage at that circulation time. Also below are images of HRP spots in
apoptosis-induced rat aortas. As the images demonstrate, the staining in the apoptosis-induced
samples (figures 2.4, 2.6, 2.8, 2.10) is much fainter than that in the controls (figures 2.1, 2.2, 2.3,
2.5, 2.7, 2.9). Both the spots and the background appear much lighter. It was for this reason that
we did not attempt a 30 second experiment; we feared that the spots would not be visible enough
to count in order to determine their frequency. We conjectured that a possible cause of this faint
staining could be the deteriorating overall health of the animal over the course of the experiment,
which took at least four hours longer than the control experiment. During the entire course of the
experiment the animal was anesthetized with pentobarbital, a drug whose effective dose (60
mg/kg delivered by intraperitoneal (IP) injection in this study, in line with our Institutional
Animal Care and Use Committee’s recommendations) is within a factor of two of its mean lethal
dose (120 mg/kg IP (34)). The American Veterinary Medical Association recommends a
euthanizing dose of three times the anesthetic dose for rodents (35). The animals' heart and
breathing rates were both observed to decrease as the experiment continued, and it is reasonable
to assume that blood pressure may have also, which would have decreased the force driving
solute into the aorta wall. If this experiment were to be repeated, it might be helpful to introduce
the drugs via a tail vein cannulation instead of a femoral cannulation. This is a more difficult
technique, but it is far less invasive and, therefore, requires less anesthesia. This might allow data
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collection from a healthier animal.
The frequency of the control HRP spots was found to be 0.80 spots per square millimeter of aorta
(9 rats) surface, in good agreement with Yu's result of 1.04 (35 rats) (32). In the apoptosis
experiments, the frequency was found, in direct contradiction of our prediction, to be a lower
0.46 (3 rats). One possible explanation would be the declining health of the animal treated with
anesthetic doses of pentobarbital for a number of hours, as discussed above. Another possible
cause is the toxicity of the chemical treatment. Although Zahn (33) reports no toxicity in rats
treated with doses of TNFA up to 100 times higher than ours, our dose of cycloheximide was
half of the lethal dose (17, 28). Still another has to do with the short half life of TNFA (on the
order of minutes). We did not attempt to predict how long it should take for a rat's aortic
endothelium to be restored from especially leaky (the condition expected as a result of the
chemical treatment) to typically leaky (the undisturbed state, once the chemicals have been
cleared and their effects neutralized), but one thing is clear from the value of the half life: after 4
hours, the amount of active drug in the rat is negligible.
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Figure 2.1: 30s control HRP spot

Figure 2.2: 30s control HRP spot
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Figure 2.3: 60s control HRP spot

Figure 2.4: apoptosis 60s HRP spot
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Figure 2.5: 60s control HRP spot

Figure 2.6: apoptosis 60s HRP spot
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Figure 2.7: 120s control HRP spot

Figure 2.8: apoptosis 120s HRP spot
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Figure 2.9: 120s control HRP

Figure 2.10: apoptosis 120s HRP spot
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2.4: Conclusion
In our study, rat aortas exhibited, paradoxically, a lower HRP spot frequency when the rats were
subjected to apoptosis-inducing chemical treatment. However, we suspect that this result may be
an artifact of the experimental procedure and that the hypothesis that apoptosis leads to a higher
spot frequency still warrants investigation.
For future work, in addition to the above suggestion for mitigating the anesthesia effects, there
are several ways to test the hypothesis that inducing apoptosis increases spot frequency. One
would be to use TNFA in combination with another drug, as shown by Zahn (33) to increase
TNFA's half life. Another would be to use polyethylene glycol-coated TNFA, which Tsutsumi
(27) has shown also has a longer half life than native TNFA. A third option, one currently under
consideration, would be to use a cytotoxic agent with a naturally longer half life. The anti-tumor
drug Paclitaxel is one such drug, and we are planning experiments using it.
Further, it would be useful to run several experiments with only TNFA and several with only
cycloheximide. This could help us tease apart their independent effects, both on spot frequency
and on overall animal health.
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